APA (7th ed.) Citation

M, S., CD, D., A, M., N, P., M, O., NG, D., . . . MY, K. (2025). VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: Long term follow-up of a phase 2 trial. Blood cancer journal, 15(1), 52. https://doi.org/10.1038/s41408-025-01265-1

Chicago Style (17th ed.) Citation

M, Swaminathan, et al. "VEN in Combination with 10-day DEC in Newly Diagnosed Elderly or Relapsed/refractory Acute Myeloid Leukemia, and High-risk Myelodysplastic Syndrome: Long Term Follow-up of a Phase 2 Trial." Blood Cancer Journal 15, no. 1 (2025): 52. https://doi.org/10.1038/s41408-025-01265-1.

MLA (9th ed.) Citation

M, Swaminathan, et al. "VEN in Combination with 10-day DEC in Newly Diagnosed Elderly or Relapsed/refractory Acute Myeloid Leukemia, and High-risk Myelodysplastic Syndrome: Long Term Follow-up of a Phase 2 Trial." Blood Cancer Journal, vol. 15, no. 1, 2025, p. 52, https://doi.org/10.1038/s41408-025-01265-1.